To:

SO/1, Pharmacy Department, the Medical City for Military and Security Services

Director of Pharmaceutical Care, Royal Hospital

Director of Pharmaceutical Care, Khoula Hospital

Pharmacist lncharge, Al Nahda Hospital

Director of Pharmaceutical Care, DGHS, Muscat Governorate

Director of Pharmaceutical Care, DGHS, Al Dakhliya Governroate

Director of Pharmaceutical Care, DGHS, South Batinah Governorate

Director of Pharmaceutical Care, DGHS, North Batinah Governorate

Director of Pharmaceutical Care, DGHS, Al Dhahira Governorate

Director of Pharmaceutical Care, DGHS, North Sharqiya Governorate

Director of Pharmaceutical Care, DGHS, South Sharqiya Governorate

Director of Pharmaceutical Care, DGHS, Musandam Governorate

Director of Pharmaceutical Care, DGHS, Dhofar Governorate

Director of Pharmaceutical Care, DGHS, Al Wusta Governorate

Director of Pharmaceutical Care, DGHS, Buraimi Governorate

Director of Pharmaceutical Care, DGMS

Pharmacist lncharge, Al Massarah Hospital

HOD, Pharmacy Department, Sultan Qaboos University Hospital

Pharmacist lncharge, The Sultan's Special Force

Pharmacist lncharge, Petroleum Development of Oman

Pharmacist lncharge, LNG Oman

After Compliments,

Please find attached our Circular No. 165/2025 dated 3/July/2025 regarding Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Associated with Semaglutide.

Copy to:

• Director General, DSC

• Director of Drug Control Department, DSC